MoonLake Immunotherapeutics
MLTX
136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 43 reducing their positions, and 15 closing their positions.
141% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $8.78M
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
18% more funds holding
Funds holding: 115 → 136 (+21)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
5.92% less ownership
Funds ownership: 100.57% → 94.65% (-5.9%)
23% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 43
32% less capital invested
Capital invested by funds: $3.43B → $2.34B (-$1.09B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.1M |
| 2 |
Millennium Management
New York
|
+$14.8M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$12.8M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$8.62M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$60.2M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$49.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$30.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$26M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$108 | -2 | Closed |
|
MLTX Hedge Fund Activity: Q1 2025 in Review
136 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2025, worth a combined $2.34B — down 32% from $3.43B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MLTX positions and 15 closed out — a net gain of 21 holders — while 33 added to existing stakes and 43 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $15.1M. The largest seller was Holocene Advisors, cutting an estimated $60.2M.
- 136 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2025, up from 115 in Q4 2024.
- Funds reported $2.34B of MoonLake Immunotherapeutics stock for Q1 2025, down 32% quarter-over-quarter.
- 36 funds opened new MoonLake Immunotherapeutics positions in Q1 2025 and 15 closed out, a net change of +21 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2025 was Logos Global Management, an estimated $15.1M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2025 was Holocene Advisors, an estimated $60.2M sold.
Based on aggregated 13F filings for Q1 2025.